Glen Eagle Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.28K Buy
+9
New +$1.45K ﹤0.01% 973
2025
Q4
– Sell
-42
Closed -$5.9K – 1110
2025
Q3
$5.9K Buy
+42
New +$5.69K ﹤0.01% 767
2020
Q4
– Sell
-110
Closed -$10.6K – 1000
2020
Q3
$10.6K Buy
+110
New +$12.7K ﹤0.01% 586
2020
Q1
– Sell
-65
Closed -$6.99K – 906
2019
Q4
$6.99K Buy
+65
New +$6.81K ﹤0.01% 660
2018
Q1
– Sell
-55
Closed -$4.27K – 699
2017
Q4
$4.27K Hold
55
– – ﹤0.01% 527
2017
Q3
$3.37K Hold
55
– – ﹤0.01% 552
2017
Q2
$2.53K Buy
+55
New +$2.67K ﹤0.01% 527

Other funds holding NBIX

Glen Eagle Advisors's NBIX Position: Q3 2026 in Review

Glen Eagle Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 9 shares worth $1.28K. The stake represents ﹤0.01% of the portfolio and ranks #973 among its holdings. This is a return to the name: Glen Eagle Advisors previously reported a position in NBIX as recently as Q3 2025.

Glen Eagle Advisors first reported a position in NBIX in Q2 2017 and has held it in 7 quarters since. The position peaked at $10.6K in Q3 2020. 772 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Glen Eagle Advisors held 9 shares of Neurocrine Biosciences worth $1.28K as of Q3 2026.
  • Neurocrine Biosciences was a new Glen Eagle Advisors position in Q3 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q3 2026, its #973 holding.
  • Glen Eagle Advisors first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 7 quarters since.
  • Glen Eagle Advisors's Neurocrine Biosciences position peaked at $10.6K in Q3 2020.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Glen Eagle Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.